Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.35 |
| ▸ | TTK | P33981 | 5/20 | 0.33 |
| ▸ | CDK2 | P24941 | 2/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 4/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | CSF1R | P07333 | 1/20 | 0.31 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22123578 | 0.95 | SYK (0.36) | MAPKAPK5PDE10APTK6TTKIDO1 | |
| SCHEMBL30385354 | 0.95 | SYK (0.36) | MAPKAPK5PDE10APTK6TTKIDO1 | |
| SCHEMBL25172090 | 0.95 | MAPKAPK5 (0.34) | MAPKAPK5PDE10APTK6TTKCDK2 | |
| SCHEMBL22124597 | 0.94 | SYK (0.37) | MAPKAPK5PDE10APTK6TTKIDO1 | |
| Hydrochloric Acid SCHEMBL25173409 | 0.94 | SYK (0.35) | MAPKAPK5PDE10APTK6TTKIDO1 | |
| SCHEMBL22124724 | 0.94 | MAPKAPK5 (0.34) | MAPKAPK5PDE10APTK6TTKCDK2 | |
| Hydrochloric Acid SCHEMBL22123465 | 0.94 | SYK (0.36) | MAPKAPK5PDE10APTK6TTKIDO1 | |
| SCHEMBL22123844 | 0.93 | HTR2A (0.35) | MAPKAPK5PDE10APTK6TTKCDK2 | |
| SCHEMBL22124583 | 0.93 | MAPKAPK5 (0.33) | MAPKAPK5PDE10APTK6TTKCDK2 | |
| SCHEMBL30385778 | 0.93 | HTR2A (0.35) | MAPKAPK5PDE10APTK6TTKCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230022724-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230022724-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | MAPKAPK5 728/4885PDE10A 2044/4885PTK6 2201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.